Who
Stephen Connelly
President and CSO
Company insider
Files Form 4 as: President and CSO, Equillium.
In numbers
- Trades disclosed
- 51
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $4.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Feb 2019
- Last trade
- 5 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 5 Jun 2026 | EQ EquilliumBiotechnology | SEC FORM 4 Sold | $91K30,975 at $2.94 | filing |
| 5 Jun 2026filed 5 Jun 2026 | EQ EquilliumBiotechnology | SEC FORM 4 Sold | $91K30,975 at $2.94 | filing |
| 4 Jun 2026filed 5 Jun 2026 | EQ EquilliumBiotechnology | SEC FORM 4 Sold | $633K200,000 at $3.16 | filing |
| 4 Jun 2026filed 5 Jun 2026 | EQ EquilliumBiotechnology | SEC FORM 4 Sold | $632K200,000 at $3.16 | filing |
| 7 Jan 2026filed 9 Jan 2026 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,150,000 at $0.00 | filing |
| 7 Jan 2026filed 9 Jan 2026 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,150,000 at $0.00 | filing |
| 29 Aug 2025filed 3 Sep 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,025,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —90,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,500 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —52,500 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,534 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,534 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code D | —175,000 | filing |
| 2 Jan 2025filed 6 Jan 2025 | EQ Equilliumoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
News
Leerink Partners Initiates Coverage on Equillium (NASDAQ:EQ)EQ · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Stephen Connelly; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.